| Literature DB >> 28775677 |
Alexander A Frolov1,2, Olesya Mokienko1,3, Roman Lyukmanov1,3, Elena Biryukova1,2, Sergey Kotov4, Lydia Turbina4, Georgy Nadareyshvily5, Yulia Bushkova6.
Abstract
Repeated use of brain-computer interfaces (BCIs) providing contingent sensory feedback of brain activity was recently proposed as a rehabilitation approach to restore motor function after stroke or spinal cord lesions. However, there are only a few clinical studies that investigate feasibility and effectiveness of such an approach. Here we report on a placebo-controlled, multicenter clinical trial that investigated whether stroke survivors with severe upper limb (UL) paralysis benefit from 10 BCI training sessions each lasting up to 40 min. A total of 74 patients participated: median time since stroke is 8 months, 25 and 75% quartiles [3.0; 13.0]; median severity of UL paralysis is 4.5 points [0.0; 30.0] as measured by the Action Research Arm Test, ARAT, and 19.5 points [11.0; 40.0] as measured by the Fugl-Meyer Motor Assessment, FMMA. Patients in the BCI group (n = 55) performed motor imagery of opening their affected hand. Motor imagery-related brain electroencephalographic activity was translated into contingent hand exoskeleton-driven opening movements of the affected hand. In a control group (n = 19), hand exoskeleton-driven opening movements of the affected hand were independent of brain electroencephalographic activity. Evaluation of the UL clinical assessments indicated that both groups improved, but only the BCI group showed an improvement in the ARAT's grasp score from 0 [0.0; 14.0] to 3.0 [0.0; 15.0] points (p < 0.01) and pinch scores from 0.0 [0.0; 7.0] to 1.0 [0.0; 12.0] points (p < 0.01). Upon training completion, 21.8% and 36.4% of the patients in the BCI group improved their ARAT and FMMA scores respectively. The corresponding numbers for the control group were 5.1% (ARAT) and 15.8% (FMMA). These results suggests that adding BCI control to exoskeleton-assisted physical therapy can improve post-stroke rehabilitation outcomes. Both maximum and mean values of the percentage of successfully decoded imagery-related EEG activity, were higher than chance level. A correlation between the classification accuracy and the improvement in the upper extremity function was found. An improvement of motor function was found for patients with different duration, severity and location of the stroke.Entities:
Keywords: ClinicalTrials.gov; brain-computer interface; exoskeleton; identifier: NCT02325947; motor imagery; paresis; rehabilitation; stroke
Year: 2017 PMID: 28775677 PMCID: PMC5517482 DOI: 10.3389/fnins.2017.00400
Source DB: PubMed Journal: Front Neurosci ISSN: 1662-453X Impact factor: 4.677
Figure 1The subject flow diagram from recruitment through analysis (Consolidated Standards of Reporting Trials flow diagram).
Demographics and main baseline characteristics of subjects by study group.
| Age, years | 58.0 [48.0; 65.0] | 58.0 [52.0; 67.0] | 0.581 |
| Males, % (n) | 61.8 (34) | 73.7% (14) | |
| Time from stroke onset, months | 8.0 [4.0; 13.0] | 8.0 [1.0; 13.0] | 0.515 |
| Subacute (1–6 months from onset) | 45.5 (25) | 47.4 (9) | |
| Chronic (>6 months from onset) | 54.5 (30) | 52.6 (10) | |
| Left hemisphere | 47.3 (26) | 63.2 (12) | |
| Right hemisphere | 52.7 (29) | 36.8 (7) | |
| Cortical | 3.6 (2) | 10.5 (2) | |
| Subcortical | 58.2 (32) | 47.4 (9) | |
| Corticosubcortical | 38.2 (21) | 42.1 (8) | |
| Initial ARAT score | 4.0 [0.0; 31.0] | 3.0 [0.0; 30.0] | 0.722 |
| Initial FMMA upper extremity score | 24.0 [12.0; 40.0] | 12.0 [11.0; 49.0] | 0.363 |
| Initial spasticity (mAS) | 3.0 [1.0; 4.0] | 3.0 [2.0; 4.0] | 0.732 |
Medians and 25 and 75% quartiles are shown.
Baseline ARAT and FMMA scores by study group and stroke period.
| ARAT total | 1.0 [0.0; 15.0] | 13.0 [0.0; 22.0] | 0.489 |
| ARAT-Grasp | 0.0 [0.0; 7.0] | 4.0 [0.0; 7.0] | 0.489 |
| ARAT-Grip | 0.0 [0.0; 4.0] | 2.0 [0.0; 5.0] | 0.565 |
| ARAT-Pinch | 0.0 [0.0; 1.0] | 2.0 [0.0; 4.0] | 0.335 |
| ARAT-Gross movement | 1.0 [0.0; 4.0] | 2.0 [0.0; 5.0] | 0.514 |
| FMMA upper extremity | 15.0 [6.0; 36.0] | 12.0 [11.0; 29.0] | 0.969 |
| FMMA-Proximal | 12.0 [7.0; 26.0] | 11.0 [10.0; 20.0] | 0.878 |
| FMMA- Distal | 2.0 [1.0; 9.0] | 1.0 [1.0; 9.0] | 0.591 |
| ARAT total | 18.5 [1.0; 39.0] | 2.0 [0.0; 30.0] | 0.331 |
| ARAT-Grasp | 8.0 [0.0; 17.0] | 0.0 [0.0; 12.0] | 0.272 |
| ARAT-Grip | 4.5 [0.0; 9.0] | 0.0 [0.0; 8.0] | 0.432 |
| ARAT-Pinch | 2.0 [0.0; 10.0] | 0.0 [0.0; 6.0] | 0.379 |
| ARAT-Gross movement | 2.0 [1.0; 6.0] | 2.0 [0.0; 6.0] | 0.701 |
| FMMA upper extremity | 30.5 [17.0; 41.0] | 12.5 [11.0; 49.0] | 0.272 |
| FMMA-Proximal | 22.0 [15.0; 29.0] | 11.5 [9.0; 27.0] | 0.259 |
| FMMA- Distal | 8.0 [2.0; 15.0] | 2.5 [1.0; 19.0] | 0.569 |
Medians and 25 and 75% quartiles are shown.
Figure 2A BCI-exoskeleton complex. A block diagram of the BCI complex used in this study: 1—32 Ag/AgCl EEC electrodes, 2—a NVX 52 encephalograph (Medical Computer Systems, Russia); 3—a computer (OS Windows 7): real time data transmission, identification of operational EEG parameters, recognition of a steering instruction; 4—a presentation monitor; 5—a hand exoskeleton (Neurobotics, Russia) with pneumatic actuators of finger extensors and spring flexors; flexed and extended exoskeleton configurations are shown. The dotted arrow denotes a visual feedback, and the solid arrow denotes a kinesthetic feedback.
Efficacy measures by ARAT and FMMA scores for each study group (all randomized patients).
| ARAT total | Before | 4.0 [0.0; 31.0] | 3.0 [0.0; 30.0] | 0–57 |
| After | 6.0 [1.0; 43.0] | 6.0 [0.0; 31.0] | ||
| <0.01 | 0.021 | |||
| ARAT-Grasp | Before | 0.0 [0.0; 14.0] | 0.0 [0.0; 12.0] | 0–18 |
| After | 3.0 [0.0; 15.0] | 1.0 [0.0; 12.0] | ||
| <0.01 | 0.394 | |||
| ARAT-Grip | Before | 0.0 [0.0; 8.0] | 0.0 [0.0; 6.0] | 0–12 |
| After | 1.0 [0.0; 10.0] | 1.0 [0.0; 7.0] | ||
| <0.01 | 0.045 | |||
| ARAT-Pinch | Before | 0.0 [0.0; 7.0] | 0.0 [0.0; 4.0] | 0–18 |
| After | 1.0 [0.0; 12.0] | 0.0 [0.0; 5.0] | ||
| <0.01 | 0.675 | |||
| ARAT-Gross movement | Before | 2.0 [0.0; 5.0] | 2.0 [0.0; 6.0] | 0–9 |
| After | 3.0 [0.0; 7.0] | 3.0 [0.0; 6.0] | ||
| <0.01 | 0.273 | |||
| FMMA upper extremity | Before | 24.0 [12.0; 40.0] | 12.0 [11.0; 49.0] | 0–66 |
| After | 29.0 [14.0; 47.0] | 17.0 [12.0; 51.0] | ||
| <0.01 | <0.01 | |||
| FMMA-Proximal | Before | 20.0 [10.0; 27.0] | 11.0 [9.0; 27.0] | 0–42 |
| After | 24.0 [13.0; 32.0] | 15.0 [11.0; 28.0] | ||
| <0.01 | <0.01 | |||
| FMMA- Distal | Before | 5.0 [1.0; 14.0] | 2.0 [1.0; 16.0] | 0–24 |
| After | 7.0 [2.0; 18.0] | 3.0 [1.0; 16.0] | ||
| <0.01 | 0.046 |
Medians and 25 and 75% quartiles are shown. The values of p < 0.05 are in red (it means statistically significant difference).
Figure 3Percent of patients reached minimal clinically important difference (MCID) by ARAT and FMMA scores in each study group.
Efficacy measures by ARAT and FMMA scores in subacute stroke patients (1–6 months from onset) for each study group.
| ARAT total | Before | 1.0 [0.0; 15.0] | 13.0 [0.0; 22.0] | 0–57 |
| After | 3.0 [0.0; 21.0] | 12.0 [0.0; 24.0] | ||
| <0.01 | 0.150 | |||
| ARAT-Grasp | Before | 0.0 [0.0; 7.0] | 4.0 [0.0; 7.0] | 0–18 |
| After | 0.0 [0.0; 10.0] | 4.0 [0.0; 6.0] | ||
| 0.036 | 0.552 | |||
| ARAT-Grip | Before | 0.0 [0.0; 4.0] | 2.0 [0.0; 5.0] | 0–12 |
| After | 0.0 [0.0; 6.0] | 3.0 [0.0; 7.0] | ||
| 0.054 | 0.181 | |||
| ARAT-Pinch | Before | 0.0 [0.0; 1.0] | 2.0 [0.0; 4.0] | 0–18 |
| After | 0.0 [0.0; 2.0] | 2.0 [0.0; 3.0] | ||
| 0.029 | 0.593 | |||
| ARAT-Gross movement | Before | 1.0 [0.0; 4.0] | 2.0 [0.0; 5.0] | 0–9 |
| After | 1.0 [0.0; 5.0] | 3.0 [0.0; 6.0] | ||
| 0.086 | 0.564 | |||
| FMMA upper extremity | Before | 15.0 [6.0; 36.0] | 12.0 [11.0; 29.0] | 0–66 |
| After | 18.0 [13.0; 46.0] | 17.0 [12.0; 31.0] | ||
| <0.01 | 0.144 | |||
| FMMA-Proximal | Before | 12.0 [7.0; 26.0] | 11.0 [10.0; 20.0] | 0–42 |
| After | 16.0 [12.0; 29.0] | 15.0 [11.0; 23.0] | ||
| <0.01 | 0.112 | |||
| FMMA- Distal | Before | 2.0 [1.0; 9.0] | 1.0 [1.0; 9.0] | 0–24 |
| After | 3.0 [1.0; 12.0] | 4.0 [1.0; 8.0] | ||
| 0.028 | 518 | |||
| Cases with MCID (ARAT), % (n) | 8.0 (2) | 0 (0) | 0–100 | |
| Cases with MCID (FMMA), % (n) | 24.0 (6) | 11.1 (1) | 0–100 |
The values of p < 0.05 are in red (it means statistically significant difference).
Efficacy measures by ARAT and FMMA scores in chronic stroke patients (>6 months from onset) for each study group.
| ARAT total | Before | 18.5 [1.0; 39.0] | 2.0 [0.0; 30.0] | 0–57 |
| After | 27.0 [3.0; 45.0] | 2.0 [1.0; 37.0] | ||
| <0.01 | 0.086 | |||
| ARAT-Grasp | Before | 8.0 [0.0; 17.0] | 0.0 [0.0; 12.0] | 0–18 |
| After | 10.0 [0.0; 18.0] | 0.0 [0.0; 12.0] | ||
| <0.01 | 1.0 | |||
| ARAT-Grip | Before | 4.5 [0.0; 9.0] | 0.0 [0.0; 8.0] | 0–12 |
| After | 6.5 [0.0; 10.0] | 0.0 [0.0; 8.0] | ||
| <0.01 | 1.0 | |||
| ARAT-Pinch | Before | 2.0 [0.0; 10.0] | 0.0 [0.0; 6.0] | 0–18 |
| After | 4.0 [0.0; 12.0] | 0.0 [0.0; 8.0] | ||
| <0.01 | 0.678 | |||
| ARAT-Gross movement | Before | 2.0 [1.0; 6.0] | 2.0 [0.0; 6.0] | 0–9 |
| After | 3.0 [1.0; 8.0] | 2.0 [1.0; 6.0] | ||
| <0.01 | 1.0 | |||
| FMMA upper extremity | Before | 30.5 [17.0; 41.0] | 12.5 [11.0; 49.0] | 0–66 |
| After | 38.0 [19.0; 53.0] | 15.5 [13.0; 56.0] | ||
| <0.01 | 0.096 | |||
| FMMA-Proximal | Before | 22.0 [15.0; 29.0] | 11.5 [9.0; 27.0] | 0–42 |
| After | 26.0 [14.0; 32.0] | 14.0 [10.0; 28.0] | ||
| <0.01 | 0.075 | |||
| FMMA- Distal | Before | 8.0 [2.0; 15.0] | 2.5 [1.0; 19.0] | 0–24 |
| After | 13.0 [3.0; 19.0] | 3.0 [2.0; 22.0] | ||
| <0.01 | 0.072 | |||
| Cases with MCID (ARAT), % (n) | 33.3 (10) | 10.0 (1) | 0–100 | |
| Cases with MCID (FMMA), % (n) | 46.7 (14) | 20.0 (2) | 0–100 |
The values of p < 0.05 are in red (it means statistically significant difference).